Skip to main content
Premium Trial:

Request an Annual Quote

Roche and CombiMatrix Strike Deal to Develop and Market Biochip Technology

NEW YORK, July 3 – Roche Diagnostics has entered into a 15-year agreement to purchase, use and resell CombiMatrix’s biochips, the companies announced Tuesday.

The worldwide, non-exclusive deal includes minimum payments by Roche to CombiMatrix during the first three years of the agreement, including royalties, payments for products, and R&D projects. The deal also stipulates that the companies develop a joint platform technology for standardized biochips.

Financial details of the agreement were not disclosed.

“This unique platform will be useful for multiple applications, including gene expression studies, single nucleotide polymorphism analysis, disease classification, pathway identification, and toxicology studies, Susanne Raehs, head of Roche Applied Science, said in a statement.

Acacia Research is the majority owner of Snoqualmie, Wash.-based CombiMatrix, which uses semiconductor technology to develop customizable microarrays. CombiMatrix remains registered for an initial public offering filed in November.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.